Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED95 comparison of remimazolam versus propofol with low-dose esketamine for gastrointestinal endoscopy sedation
ChiCTR2400085180Phase 4Completed
- Sponsor
- Zhuji People's Hospital of Zhejiang Province
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of remimazolam, propofol and esketamine (4 arms), sponsored by Zhuji People's Hospital of Zhejiang Province. Primary endpoints: 95% effective dose of remimazolam, 95% effective dose of propofol and 4 more. Started Jun 2024; status: completed.
02
Drugs
remimazolampropofolesketamine
Beyond the preview
Go deeper on ChiCTR2400085180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085180.